Clinical Trial Update: Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine and pemetrexed in primary unknown adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Adenocarcinoma | Phase 2 | Status: COMPLETED